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Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the
discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an
attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase
inhibitor PLX4032 that validate oncogene-targeted melanoma therapy.Traditional approaches to treat advanced
metastatic melanoma benefit only a small
subset of patients and provide response
rates rarely above 20%. A new wave of
therapeutic strategies may drastically
change this dismal outlook as more
specific pharmacologic inhibitors, well-
defined molecular targets, and immuno-
therapies are significantly impacting
disease outcome.
Melanomas are comprised of clinically
and genetically distinct subgroups (Curtin
et al., 2005), indicating the potential for
individualized therapies. The discovery
that melanomas harbor activating muta-
tions in the serine-threonine BRAF kinase
in approximately 50% of patients (the
V600E mutation being the most common)
(Davies et al., 2002) prompted an intense
search for compounds to inhibit BRAF
activity. The first clinical drug candidate,
sorafenib, provided disappointing results
even when combined with chemotherapy
(Flaherty et al., 2008; Hauschild et al.,
2009). Sorafenib is a broad-spectrum
kinase inhibitorwithhigherpotencyagainst
CRAF than BRAF; therefore, searching for
more selective inhibitors was necessary
to validate the effectiveness of targeting
mutant BRAF in melanoma.
As recently reported in Nature, Bollag
et al. (2010) used a structure-guided
approach to develop a kinase inhibitor,
PLX4032 (also known as RG7204), that
is selective for BRAF V600E. PLX4032 is
a well tolerated, orally available small
molecule inhibitor with remarkable selec-
tivity against BRAF mutant cells in vitro
and in mouse xenograft models (Bollag
et al., 2010; Lee et al., 2010). Despite
encouraging preclinical studies, no tumor
regression was observed in the initial
phase 1 clinical trial with PLX4032, eventhough phosphorylated ERK (pERK)
levels were reduced in tumor biopsies.
PLX4032 was then reformulated in a
collaboration between Plexxikon and
Roche to allow higher bioavailability. Re-
formulated PLX4032 achieved greater
than 80% inhibition of pERK levels and
strong tumor response (Bollag et al.,
2010).
In The New England Journal of
Medicine, Flaherty et al. (2010) provide
the breakthrough clinical evidence
showing that PLX4032 treatment of
metastatic melanomas harboring the
BRafV600E mutation results in complete or
partial tumor regression in the majority of
patients. In an extension phase of the
study using the maximum tolerated dose,
81% of patients (26 of 32) had tumor re-
gression according to the Response Eval-
uation Criteria in Solid Tumors (RECIST)
(Flaherty et al., 2010). Responses are not
observed in patients with tumors carrying
wild-type BRAF, indicating that onco-
gene-targeted therapy via mutant BRAF
inhibition is a specific and valid strategy
exclusively for the treatment of BRAF
mutant tumors.
These studies not only establish mutant
BRAF as a bona fide therapeutic target
but also position PLX4032 as the first
selective BRAF inhibitor to display clinical
activity in BRAF mutant melanomas.
Although debates arise on the issue of
selectivity of anticancer drugs and their
ability to kill tumor cells given the complex
signaling networks involved, PLX4032
data indicate that being ‘‘on-target’’ has
its advantages. First, the high blood
levels needed to obtain a clinical re-
sponse may not have been achieved
with a less selective and thus potentially
more toxic compound. Second, the clin-Cancer Cell 18ical response can be obscured when too
many ‘‘target hits’’ are involved. This
may not be a disadvantage if positive clin-
ical results are obtained, but if therapies
are unsuccessful, knowing where and
how to troubleshoot is key. Finally, with
the multiple agents available for combina-
tions, knowledge of a drug’s mode of
action will facilitate compound selection
and patient assignment for proper
individualized therapy. So far, analysis of
tumor biopsies indicate that PLX4032
‘‘hits’’ its intended target, assessed via
decreases in intratumoral levels of pERK,
which best correlate with response,
and near-complete inhibition of ERK
signaling seems to be necessary to cause
significant tumor regression (Bollag et al.,
2010).
Encouragingly, side effects of PLX4032
are manageable and consist of grade 2–3
rashes, fatigue, joint pain, and cutaneous
squamous-cell carcinomas (SCC), kera-
toacanthoma-type lesions. These cu-
taneous lesions appeared in 31% of
patients; however, they are well differenti-
ated and have low invasive potential
(Flaherty et al., 2010). They appeared in
sun-exposed skin areas and were also
observed following sorafenib, XL281,
and GSK2118436 treatments, suggesting
that pre-existing oncogenic mutations
may potentiate RAF inhibitor-mediated
side effects. Interestingly, PLX4032 ap-
peared to have no effects on benign
nevus progression or regression (Bollag
et al., 2010); the senescence state of
these lesions could account for this lack
of response.
So far, the biggest concern regarding
PLX4032 and likely all BRAF inhibitors
arises from the fact that responsive
tumors eventually acquire resistance to, October 19, 2010 ª2010 Elsevier Inc. 301
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progression-free survival is estimated at
more than 7months; however, themedian
overall survival rate is not yet available.
Why and how resistance is acquired is
being intensively studied. Subpopulations
of non-drug-responsive cells may be pre-
sent in the tumor and slowly overtake the
drug-sensitive populations, or possibly all
tumor cells respond to the compound but
not to the same extent, allowing some
cells to survive while they rewire for
growth. The only way to address this issue
is to study the phenomenon in preclinical
models that closely mimic what occurs
in the clinic, and importantly, to have
access to patient samples following clin-
ical trials to validate the findings. Resis-
tance (acquired and/or intrinsic) could
involve multiple counterbalancing path-
ways, molecular culprits, or genetic alter-
ations; however, so far Flaherty et al.
report that ‘‘gatekeeper’’ BRAF mutations
have not been detected (Flaherty et al.,
2010).
The melanoma field is no longer facing
an insurmountable treatment wall and
multiple options are emerging now that
mutant BRAF-based therapy shows posi-
tive outcomes. For example, trials could
combine BRAF inhibitors with com-
pounds targeting other melanoma-rele-
vant signaling networks (such as the
PI3K pathway) or combinations with
immunotherapy (such as the recently clin-
ically successful ipilimumab, which
targets CTLA4) (Hodi et al., 2010). The
emergence of other specific BRAF inhibi-302 Cancer Cell 18, October 19, 2010 ª2010tors such as GSK2118436 may soon
confirm the robustness of targeting
mutant BRAF while expanding the arsenal
of antimelanoma inhibitors available to
patients. It is hoped that each clinical trial
is preceded by solid preclinical data as
multiple models are available to system-
atically assess the validity of combina-
tions. For example, a new mouse genetic
model of BRafV600E/Pten/mimics mela-
noma progression (Dankort et al., 2009).
In addition, multiple human xenograft
models exist that reflect the diversity of
melanoma subgroups.
Positive results from the ongoing trials
could sway the FDA toward an early
approval despite the eventual recurrence
of tumors. Regardless of the encouraging
results, the melanoma field remains
challenged with several issues such as
(1) acquired resistance to PLX4032 and
other BRAF inhibitors, (2) some BRAF
mutant melanoma tumors that do not
respond to BRAF inhibitors (intrinsic resis-
tance), and (3) wild-type BRAF in 50% of
melanomas. There are also many open
questions regarding the signaling net-
works involved in melanoma: even if an
ideal target is identified, how long and to
what extent will compensatory mecha-
nisms take over? Tumor heterogeneity
would indicate that not all cells within
one tumor are killed or respond equally
(Roesch et al., 2010).Will this play a signif-
icant role in future treatment strategies?
Will we need two therapies, one to elimi-
nate the majority of the cells and another
to target the minor subpopulation(s)?Elsevier Inc.REFERENCES
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